DV
Dividend Vision

FBLG — FibroBiologics, Inc. Common Stock

FibroBiologics, Inc. Common Stock (FBLG)

Total return is -99.3% over the past 2.5 years, 162.2 points behind SPY at 62.9%. Its deepest 1-year drawdown was 95.0%.

FBLG is a single-stock equity holding that tracks FibroBiologics, Inc., a clinical-stage biopharmaceutical company. The fund carries no distribution yield and does not pay regular dividends, making it unsuitable for income-focused strategies. This holding appeals primarily to growth-oriented investors seeking exposure to the company's pipeline development and potential long-term capital appreciation rather than current income generation.

FBLG key facts

Asset type
Stock
Asset class
Equity
Inception date
01/30/2024
Last close
$1.06
Market cap
$4,348,923
Average volume
181100.0
Beta
1.167
Payout ratio
0.0
Forward P/E
0.0
EPS
$-7.02